You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

RYTHMOL SR Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Rythmol Sr, and when can generic versions of Rythmol Sr launch?

Rythmol Sr is a drug marketed by Glaxosmithkline Llc and is included in one NDA.

The generic ingredient in RYTHMOL SR is propafenone hydrochloride. There are eleven drug master file entries for this compound. Twenty suppliers are listed for this compound. Additional details are available on the propafenone hydrochloride profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Rythmol Sr

A generic version of RYTHMOL SR was approved as propafenone hydrochloride by WATSON LABS on October 24th, 2000.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for RYTHMOL SR?
  • What are the global sales for RYTHMOL SR?
  • What is Average Wholesale Price for RYTHMOL SR?
Drug patent expirations by year for RYTHMOL SR
Drug Prices for RYTHMOL SR

See drug prices for RYTHMOL SR

Recent Clinical Trials for RYTHMOL SR

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
GlaxoSmithKlinePhase 1
MedtronicPhase 3
Mayo ClinicPhase 3

See all RYTHMOL SR clinical trials

Pharmacology for RYTHMOL SR
Drug ClassAntiarrhythmic
Paragraph IV (Patent) Challenges for RYTHMOL SR
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
RYTHMOL SR Extended-release Capsules propafenone hydrochloride 325 mg 021416 1 2006-11-07
RYTHMOL SR Extended-release Capsules propafenone hydrochloride 225 mg and 425 mg 021416 1 2006-10-11

US Patents and Regulatory Information for RYTHMOL SR

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Glaxosmithkline Llc RYTHMOL SR propafenone hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 021416-001 Sep 4, 2003 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Glaxosmithkline Llc RYTHMOL SR propafenone hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 021416-002 Sep 4, 2003 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Glaxosmithkline Llc RYTHMOL SR propafenone hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 021416-003 Sep 4, 2003 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for RYTHMOL SR

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Glaxosmithkline Llc RYTHMOL SR propafenone hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 021416-001 Sep 4, 2003 ⤷  Sign Up ⤷  Sign Up
Glaxosmithkline Llc RYTHMOL SR propafenone hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 021416-003 Sep 4, 2003 ⤷  Sign Up ⤷  Sign Up
Glaxosmithkline Llc RYTHMOL SR propafenone hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 021416-002 Sep 4, 2003 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for RYTHMOL SR

See the table below for patents covering RYTHMOL SR around the world.

Country Patent Number Title Estimated Expiration
China 1120312 ⤷  Sign Up
Poland 310966 ⤷  Sign Up
Israel 109097 ⤷  Sign Up
Hungary T73248 ⤷  Sign Up
Hungary 9502879 ⤷  Sign Up
Denmark 0691843 ⤷  Sign Up
European Patent Office 0691843 MICRO-COMPRIME RETARD DE DERIVES DE BETA-PHENYLPROPIOPHENONE (RETARDED-ACTION MICROTABLET MADE OF BETA-PHENYLPROPIOPHENONE DERIVATIVES) ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.